Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    PureGym tackles doomscrolling with joy strolling

    mayo 30, 2026

    Moment Blue Origin rocket explodes during test in Florida

    mayo 30, 2026

    Why the SAVE Act Matters

    mayo 30, 2026
    Facebook X (Twitter) Instagram
    Trending
    • PureGym tackles doomscrolling with joy strolling
    • Moment Blue Origin rocket explodes during test in Florida
    • Why the SAVE Act Matters
    • White House says Trump is in «excellent health» in results from physical
    • ASCO News: Bristol and Pfizer report favorable results — Day 1
    • Where Are Sherri Papini’s Kids Now? Insights & Updates
    • Angels can’t overcome two homers from Yandy Díaz in loss to Rays
    • Judge orders Donald Trump to remove his name from Washington icon
    Facebook X (Twitter) Instagram
    Al Punto Hoy
    • National News
    • International News
    • Politics
    • Economy
    • Health
    • Entertainment
    • Sports
    Al Punto Hoy
    Portada » ASCO News: Bristol and Pfizer report favorable results — Day 1
    Health

    ASCO News: Bristol and Pfizer report favorable results — Day 1

    Al Punto Hoy from ANASTACIO ALEGRIABy Al Punto Hoy from ANASTACIO ALEGRIAmayo 30, 2026No hay comentarios1 Views
    Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Tumblr Email
    ASCO News: Bristol and Pfizer report favorable results — Day 1
    Share
    Facebook Twitter LinkedIn Pinterest Email
    ASCO News: Bristol and Pfizer report favorable results — Day 1


    Chicago, where thousands in the cancer world gather each year.Adam Feuerstein/STAT

    Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

    Matthew Herper covers medical innovation — both its promise and its perils.

    Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.

    You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here.  

    We’re ASCOmaxxing.

    Rest assured, this will not require Adam Feuerstein, Matthew Herper or Angus Chen to hammer on their jawlines. They will, however, be scouring the ASCO annual meeting to bring you the cancer news, analysis and event coverage you crave.

    STAT+ Exclusive Story

    Already have an account? Log in

    STAT+



    STAT+

    This article is exclusive to STAT+ subscribers

    Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

    Already have an account? Log in

    View All Plans

    To read the rest of this story subscribe to STAT+.

    Subscribe

    1. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.

    2. Senior Writer, Medicine, Editorial Director of Events

      Matthew Herper covers medical innovation — both its promise and its perils.

    3. Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Al Punto Hoy from ANASTACIO ALEGRIA
    • Website

    Related Posts

    First-in-Class Hepatitis B Drug Shows Promise for ‘Functional Cure’ in Early Trials

    mayo 29, 2026

    Ecopipam for Tourette Syndrome: Phase 3 Clinical Trial results in!

    mayo 28, 2026

    Kailera, AstraZeneca, Chan Zuckerberg: Readout Newsletter

    mayo 27, 2026
    Leave A Reply Cancel Reply

    Top Posts

    Pharmalittle: Trump getting more credit than Biden on drug prices

    marzo 13, 2026269

    Birthright Citizenship Case at Supreme Court Affects All Americans

    abril 1, 2026226

    Nearly locked into play-in, Warriors try to improve seeding vs. Wizards

    marzo 27, 2026162

    Links 3/30/2026 | naked capitalism

    marzo 30, 2026153
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo

    Subscribe to Updates

    Get the latest news from alpuntohoy.

    About Us
    About Us

    Welcome to AlPuntoHoy, your trusted source for timely, accurate, and engaging news from around the world. Our mission is to keep readers informed with reliable reporting, insightful analysis, and comprehensive coverage across a wide range of topics.

    WhatsApp
    Most Popular

    Pharmalittle: Trump getting more credit than Biden on drug prices

    marzo 13, 2026269

    Birthright Citizenship Case at Supreme Court Affects All Americans

    abril 1, 2026226

    Nearly locked into play-in, Warriors try to improve seeding vs. Wizards

    marzo 27, 2026162
    Categorías
    • Economy
    • Entertainment
    • Health
    • International News
    • National News
    • Politics
    • Sports
    • Uncategorized
    © 2026 All rights reserved AlPuntoHoy.
    • Home
    • About Us
    • Contact Us
    • Privacy Policy

    Type above and press Enter to search. Press Esc to cancel.